PRESS RELEASE published on 05/19/2025 at 07:51, 1 year 1 month ago AB Science reçoit un brevet chinois protégeant le masitinib dans le traitement du Covid-19 jusqu’en 2041, ajoutant ainsi une indication supplémentaire bénéficiant d’une protection à long terme de la propriété intellectuelle AB Science reçoit un brevet chinois pour le masitinib dans le traitement du COVID-19 jusqu'en 2041, renforçant sa protection en propriété intellectuelle COVID-19 Propriété Intellectuelle AB Science Masitinib Brevet Chinois
PRESS RELEASE published on 05/19/2025 at 07:51, 1 year 1 month ago AB Science receives Chinese patent protecting masitinib in the treatment of Covid-19 until 2041, adding one more indication with long term intellectual property protection AB Science receives Chinese patent protecting masitinib in the treatment of COVID-19 until 2041, providing long-term intellectual property protection. Collaboration with University of Chicago for COVID-19 research Intellectual Property COVID-19 Treatment AB Science Masitinib Chinese Patent
BRIEF published on 05/01/2025 at 10:11, 1 year 2 months ago AB Science reporte la publication de son rapport financier annuel 2024 Euronext Paris Rapport Financier Publication Retardée AB Science Masitinib
BRIEF published on 05/01/2025 at 10:11, 1 year 2 months ago AB Science postpones the publication of its 2024 annual financial report Euronext Paris Financial Report Publication Delayed AB Science Masitinib
PRESS RELEASE published on 05/01/2025 at 10:06, 1 year 2 months ago AB Science publiera son rapport financier annuel 2024 le vendredi 9 mai 2025 AB Science annonce le report de la publication de son rapport financier annuel 2024 au 9 mai 2025 pour achever l'audit. La société se spécialise dans les inhibiteurs de protéines kinases Rapport Financier Audit AB Science Masitinib Inhibiteurs De Protéines Kinases
PRESS RELEASE published on 05/01/2025 at 10:06, 1 year 2 months ago AB Science will publish its 2024 annual financial report on May 9, 2025 AB Science postpones the publication of its 2024 annual financial report to May 9, 2025, to allow auditors more time for audit work. The report will be released after trading hours Financial Report Postponement Auditors AB Science 2024 Annual Report
BRIEF published on 04/23/2025 at 19:04, 1 year 2 months ago EMA Grants Orphan Drug Status to AB8939 for AML Treatment AB Science AB8939 EMA Approval Acute Myeloid Leukemia Orphan Designation
BRIEF published on 04/23/2025 at 19:04, 1 year 2 months ago L'EMA accorde le statut de médicament orphelin à AB8939 pour le traitement de la LAM AB Science AB8939 Approbation De L'EMA Leucémie Myéloïde Aiguë Désignation D'orphelin
PRESS RELEASE published on 04/23/2025 at 18:59, 1 year 2 months ago AB Science announces that EMA granted orphan drug status to AB8939 for the treatment of acute myeloid leukemia AB Science's AB8939 granted orphan drug designation by EMA in EU for treating acute myeloid leukemia, showing significant benefit over current therapies. Preclinical data reveals efficacy and safety Orphan Drug Designation AB Science EMA AB8939 Acute Myeloid Leukemia
PRESS RELEASE published on 04/23/2025 at 18:59, 1 year 2 months ago La molécule AB8939 obtient la désignation de médicament orphelin auprès de l'EMA dans le traitement de la leucémie myéloïde aigue La molécule AB8939 obtient la désignation de médicament orphelin dans l'Union Européenne pour le traitement de la leucémie myéloïde aigüe. AB Science fait un pas important dans le domaine de la recherche médicale Traitement AB Science Médicament Orphelin AB8939 Leucémie Myéloïde Aiguë
Published on 07/14/2026 at 11:30, 39 minutes ago FireFox Gold Expands Drill Program at Mustajärvi and Commences Drilling at the Sarvi Project in Lapland, Finland
Published on 07/14/2026 at 01:45, 10 hours 24 minutes ago Arctic Fox Lithium Approved for Trading on the OTCQB Venture Market and Announces DTC Eligibility
Published on 07/14/2026 at 00:01, 12 hours 8 minutes ago Captor Capital Announces Delay in its Annual Filings
Published on 07/13/2026 at 23:10, 12 hours 59 minutes ago Galaxy Ventures Inc. Announces Director Resignation
Published on 07/13/2026 at 21:35, 14 hours 34 minutes ago ATHA Energy Announces Corporate Activities Update
Published on 07/14/2026 at 11:20, 49 minutes ago Turkiye Garanti Bankasi A.S.: Announcement regarding Corporate Governance Rating Agreement
Published on 07/14/2026 at 11:05, 1 hour 4 minutes ago Newronika Receives CE Mark for αDBS®, Advancing Its Mission to Make Adaptive Therapy the Standard of Care
Published on 07/14/2026 at 11:05, 1 hour 4 minutes ago Yilu Liu, Yushan Yan, Johann W. Kolar have been chosen as laureates of Global Energy Prize 2026
Published on 07/14/2026 at 11:00, 1 hour 9 minutes ago Growth financing: SIXT places EUR 500 million bond – order book more than three times oversubscribed
Published on 07/14/2026 at 10:58, 1 hour 11 minutes ago EQS-Adhoc: Semperit AG Holding: Operating earnings in Q2 2026 significantly above the prior-year figure; full-year earnings forecast raised
Published on 07/13/2026 at 18:00, 18 hours 9 minutes ago CP Icade - Icade reprend 100% de la propriété de la Tour Eqho à la Défense
Published on 07/13/2026 at 18:00, 18 hours 9 minutes ago PR Icade - Icade regains full ownership of the Eqho Tower in La Défense
Published on 07/13/2026 at 18:00, 18 hours 9 minutes ago THERMADOR GROUPE : publication du chiffre d'affaires semestriel 2026